GLP-1 & BeyondExplore the worldwide timeline →

WPF flagship programsThe Human Peptide Project™The Living Peptide Record™

English

Worldwide Study Finder

Loading registry information…

Worldwide Study Finder | World Peptide Foundation

Research across borders

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find studies Explore world registries Peptide directory

Find a study

Enter a peptide, product, condition or location. Try generic names, brand names and development codes separately. Results are registry search matches, not automatically verified links to a WPF peptide record.

Search terms are sent to ClinicalTrials.gov and appear in the page URL. Do not enter personal or medical identifying information. Registry records are served with up to a one-hour cache; registry updates themselves can lag real-world changes.

Registry search results

Matching records; showing 20 on this page, newest registry updates first. Search checked 2026-10-07 18:51 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Not applicableCompletedINTERVENTIONAL

Imaging Pituitary ActiVation by Exendin

ClinicalTrials.gov · NCT03923114 · Registry updated: 2024-05-22

Condition / research focus: Diabetes Mellitus, Type 2
Sponsor: Radboud University Medical Center
Countries with listed sites: Netherlands
Registry dates and results: Start: 2019-05-23. Completion: 2024-04-03 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Ga-68-NODAGA-exendin-4 PET/CT (radiation)

Where the study takes place — 1 listed sites

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

Radboud university medical center
Nijmegen, Gelderland, Netherlands
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Explore the world’s study registries

These links open external registries; their records are not merged into the results above. WHO ICTRP provides a broader search across contributing registries. Search the same generic name, aliases and development codes in relevant regions. One multinational study may appear in more than one registry, so compare registration identifiers before counting it twice.

Worldwide

Africa

Pan African Clinical Trial Registry ↗

Americas

Phase 3TerminatedINTERVENTIONAL

A Trial to Determine the Efficacy and Safety of Presendin in IIH

ClinicalTrials.gov · NCT05347147 · Registry updated: 2024-04-24

Condition / research focus: Idiopathic Intracranial Hypertension
Sponsor: Invex Therapeutics Ltd.
Countries with listed sites: Australia · Germany · Israel · New Zealand · United Kingdom · United States
Registry dates and results: Start: 2022-11-18. Completion: 2023-10-20 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Presendin (drug)
Placebo (drug)

Where the study takes place — 24 listed sites

UCHealth Sue Anschutz-Rodgers Eye Center - Anschutz Medical Campus
Aurora, Colorado, United States
Site recruitment: Not reported
University of Miami Leonard M. Miller School of Medicine (UMMSM) - Bascom Palmer Eye Institute
Miami, Florida, United States
Site recruitment: Not reported
University of Minnesota Health
Minneapolis, Minnesota, United States
Site recruitment: Not reported
New York Eye and Ear Infirmary of Mount Sinai
New York, New York, United States
Site recruitment: Not reported
Vanderbilt Eye Institute
Nashville, Tennessee, United States
Site recruitment: Not reported
The University of Texas Southwestern Medical Center
Dallas, Texas, United States
Site recruitment: Not reported
Neuro-Eye Clinical Trials, Inc
Houston, Texas, United States
Site recruitment: Not reported
Liverpool Hospital
Liverpool, New South Wales, Australia
Site recruitment: Not reported
Sydney Eye Hospital
Sydney, New South Wales, Australia
Site recruitment: Not reported
Vision SA
Kent Town, South Australia, Australia
Site recruitment: Not reported
Alfred Health - The Alfred Centre
Melbourne, Victoria, Australia
Site recruitment: Not reported
University Hospital Bonn
Bonn, Germany
Site recruitment: Not reported
Universitätsklinikum Freiburg
Freiburg im Breisgau, Germany
Site recruitment: Not reported
Universitaetsmedizin Mainz
Mainz, Germany
Site recruitment: Not reported
University Hospital Muenster, Department Ophthalmology Clinical Trials in Ophthalmology (CTO)
Münster, Germany
Site recruitment: Not reported
Rambam Medical Center
Haifa, Israel
Site recruitment: Not reported
Bnai Zion Medical Center
Haifa, Israel
Site recruitment: Not reported
The Edith Wolfson Medical Center
Holon, Israel
Site recruitment: Not reported
Shaare Zedek Medical Center
Jerusalem, Israel
Site recruitment: Not reported
Hadassah Medical Center - Ein Karem
Jerusalem, Israel
Site recruitment: Not reported
Pade Medical Center (Poriya)
Tiberias, Israel
Site recruitment: Not reported
New Zealand Clinical Research (Aukland)
Auckland, New Zealand
Site recruitment: Not reported
University Hospitals Birmingham NHS Foundation Trust - Queen Elizabeth Hospital Birmingham
Birmingham, United Kingdom
Site recruitment: Not reported
Guy's and St Thomas' NHS Foundation Trust
London, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

SEMAGLUTIDE VERSUS GLP-1 RECEPTOR AGONISTS. EFFECTIVENESS , SAFETY AND QUALITY OF LIFE IN PATIENTS WITH DIABETES MELLITUS 2. OBSERVATIONAL, PROSPECTIVE AND MULTICENTER STUDY. SEVERAL STUDY.

ClinicalTrials.gov · NCT05136287 · Registry updated: 2024-02-28

Condition / research focus: Weight Loss; Diabetes Mellitus, Type 2; Quality of Life; Safety Issues
Sponsor: Jose Seijas Amigo
Countries with listed sites: Spain
Registry dates and results: Start: 2022-02-01. Completion: 2024-01-01 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

GLP-1 receptor agonist (drug)

Where the study takes place — 11 listed sites

Centro de Salud de Culleredo
Culleredo, A Coruña, Spain
Site recruitment: Not reported
Centro de Salud de Fene
Fene, A Coruña, Spain
Site recruitment: Not reported
Centro de Salud de Ribeira
Ribeira, A Coruña, Spain
Site recruitment: Not reported
Hospital Clínico Universitario de Santiago de Compostela
Santiago de Compostela, A Coruña, Spain
Site recruitment: Not reported
Centro de Salud de Ribadeo
Ribadeo, Lugo, Spain
Site recruitment: Not reported
Centro de Salud de Vilalba
Vilalba, Lugo, Spain
Site recruitment: Not reported
Centro de Salud de O Carballiño
O Carballiño, Ourense, Spain
Site recruitment: Not reported
Centro de Salud Valmiñor
Nigrán, Pontevedra, Spain
Site recruitment: Not reported
Centro de Salud de O Ventorrillo
A Coruña, Spain
Site recruitment: Not reported
Centro de Salud de San Roque
Lugo, Spain
Site recruitment: Not reported
Centro de Salud Virxe Peregrina
Pontevedra, Spain
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR)

ClinicalTrials.gov · NCT01524705 · Registry updated: 2023-12-29

Condition / research focus: Type 2 Diabetes
Sponsor: University of Washington
Countries with listed sites: United States
Registry dates and results: Start: 2012-08. Completion: 2014-07 (may be estimated). Results are posted in this registry.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Insulin Glargine (drug) — also listed as: Basal insulin
Metformin (drug) — also listed as: Generic metformin
Prandial insulin (drug) — also listed as: Aspart or glulisine or lispro
Exenatide (drug) — also listed as: Glucagon-like polypeptide-1-agonist (GLP-1-agonist), Byetta

Where the study takes place — 12 listed sites

So Calif. Permanente Medical Group
San Diego, California, United States
Site recruitment: Not reported
University of Miami
Miami, Florida, United States
Site recruitment: Not reported
Atlanta Diabetes Associates
Atlanta, Georgia, United States
Site recruitment: Not reported
Joslin Diabetes Center
Boston, Massachusetts, United States
Site recruitment: Not reported
International Diabetes Center
Minneapolis, Minnesota, United States
Site recruitment: Not reported
Washington University
St Louis, Missouri, United States
Site recruitment: Not reported
Kaledia Health of Western New York
Buffalo, New York, United States
Site recruitment: Not reported
Diabetes Care Center
Durham, North Carolina, United States
Site recruitment: Not reported
Oregon Health and Science University
Portland, Oregon, United States
Site recruitment: Not reported
University of Vermont
Colchester, Vermont, United States
Site recruitment: Not reported
University of Washington
Seattle, Washington, United States
Site recruitment: Not reported
Washington State University Spokane, College of Pharmacy Spokane WA 99202 USA
Spokane, Washington, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Worldwide Study Finder

Worldwide Study Finder

Find a study

Registry search results

Imaging Pituitary ActiVation by Exendin

Explore the world’s study registries

Worldwide

Africa

Americas

Exenatide-test for Diagnosing Endogenous Hyperinsulinemic Hypoglycemia

A Trial to Determine the Efficacy and Safety of Presendin in IIH

GLP-1 Receptor Agonist Therapy and Albuminuria in Patients With Type 2 Diabetes

Haemodynamic Effects of GLP-1 and Glucagon in Healthy Male Volunteers

An Investigation Into the Effect of Dapagliflozin on Ketogenesis in Type 1 Diabetes

SEMAGLUTIDE VERSUS GLP-1 RECEPTOR AGONISTS. EFFECTIVENESS , SAFETY AND QUALITY OF LIFE IN PATIENTS WITH DIABETES MELLITUS 2. OBSERVATIONAL, PROSPECTIVE AND MULTICENTER STUDY. SEVERAL STUDY.

Visualizing Beta Cells in Patients With a History of Gestational Diabetes

FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR)

A GLP-1 Receptor PET Imaging Substudy Within the VER-A-T1D Trial Investigating the Effects on Beta Cell Mass

GLP1R-imaging in Hypoglycemia

Exendin PET/CT for Imaging of Paragangliomas

The Effect of GLP-1 Agonists Versus OCs on Reproductive Disorders and Cardiovascular Risks in Overweight PCOS

The Clinical Application of 68Ga-NOTA-exendin-4 PET/CT in Detecting Insulinoma

Safety and Efficacy of PB-119 in Subjects With Type 2 Diabetes and Not Well-controlled by Metformin Monotherapy

Safety and Efficacy of Pegylated Exenatine Injection (PB-119) in Drug-naïve T2DM Subjects

Can Exenatide Prevent Increase in EGP in Response to Dapagliflozin-induced Increase in Glucosuria

Effect of Chronic Exenatide Therapy on Beta Cell Function and Insulin Sensitivity in T2DM

Impact of Exenatide on Cardiovascular Exercise Performance in Type 2 Diabetes

Quantitative GLP-1 Receptor Imaging Correlated to ex Vivo Distribution of In-111-exendin

Asia

Middle East

Europe

Oceania